| Literature DB >> 21448824 |
S Nikol1.
Abstract
The world-wide largest angiogenesis gene therapy trial in 525 patients suffering from critical limb ischemia and treated with the non-viral gene construct for fibroblast growth factor (NV1FGF) or placebo was negative for all endpoints. Also, stem cell or progenitor cell therapy did no reveal clinical benefit in patients with peripheral artery disease. Data from large randomized placebo-controlled are still not available. © Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21448824 DOI： 10.1055/s-0031-1274561
Source DB: PubMed Journal: Dtsch Med Wochenschr ISSN： 0012-0472 Impact factor: 0.628